Financial Snapshot

Revenue
$419.4K
TTM
Gross Margin
-38.22%
TTM
Net Earnings
-$8.034M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
525.97%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$5.963M
Q3 2024
Cash
Q3 2024
P/E
-0.2888
Nov 29, 2024 EST
Free Cash Flow
-$4.319M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020
Revenue $253.6K $511.2K $6.353M $2.181M
YoY Change -50.4% -91.95% 191.23%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020
Revenue $253.6K $511.2K $6.353M $2.181M
Cost Of Revenue $474.6K $432.4K $850.7K $703.0K
Gross Profit -$221.0K $78.84K $5.502M $1.478M
Gross Profit Margin -87.15% 15.42% 86.61% 67.77%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020
Selling, General & Admin $4.242M $1.304M $1.115M $1.458M
YoY Change 225.36% 16.89% -23.5%
% of Gross Profit 1653.63% 20.27% 98.62%
Research & Development $691.8K $525.6K $5.511M $806.7K
YoY Change 31.63% -90.46% 583.15%
% of Gross Profit 666.62% 100.16% 54.57%
Depreciation & Amortization $50.32K $32.77K $30.84K $27.87K
YoY Change 53.56% 6.26% 10.66%
% of Gross Profit 41.57% 0.56% 1.89%
Operating Expenses $4.934M $1.829M $6.626M $2.265M
YoY Change 169.7% -72.39% 192.6%
Operating Profit -$5.155M -$1.750M -$1.124M -$786.2K
YoY Change 194.47% 55.72% 42.97%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020
Interest Expense -$2.724M -$4.504M -$3.173M -$2.629M
YoY Change -39.53% 41.97% 20.67%
% of Operating Profit
Other Income/Expense, Net $5.296M -$43.24K $37.52K $368.1K
YoY Change -12348.27% -215.25% -89.81%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020
Pretax Income -$3.814M -$6.177M -$4.259M -$3.047M
YoY Change -38.26% 45.03% 39.77%
Income Tax $250.00 $500.00 $1.000K $1.000K
% Of Pretax Income
Net Earnings -$3.986M -$6.182M -$4.252M -$3.034M
YoY Change -35.51% 45.39% 40.15%
Net Earnings / Revenue -1572.12% -1209.23% -66.93% -139.08%
Basic Earnings Per Share -$0.99 -$2.61
Diluted Earnings Per Share -$1.01 -$1.11 -$0.76 -$0.54

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020
Cash & Short-Term Investments $2.142M $264.9K $115.4K $191.7K
YoY Change 708.88% 129.52% -39.8%
Cash & Equivalents $2.142M $264.9K $115.4K $191.7K
Short-Term Investments
Other Short-Term Assets $4.403M $269.6K $225.9K $352.2K
YoY Change 1533.01% 19.36% -35.86%
Inventory $466.2K $518.6K $689.0K $1.040M
Prepaid Expenses
Receivables $231.3K $45.97K $146.4K $859.4K
Other Receivables $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $7.243M $1.099M $1.177M $2.443M
YoY Change 559.02% -6.6% -51.83%
Property, Plant & Equipment $71.28K $33.95K $107.6K $73.41K
YoY Change 109.96% -68.45% 46.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $242.7K $9.550K
YoY Change
Total Long-Term Assets $541.2K $198.2K $216.9K $163.2K
YoY Change 173.03% -8.6% 32.9%
Total Assets $7.784M $1.297M $1.394M $2.606M
YoY Change
Accounts Payable $506.2K $758.7K $588.7K $1.377M
YoY Change -33.28% 28.88% -57.25%
Accrued Expenses $13.65K $13.00K $46.80K $0.00
YoY Change 5.0% -72.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $8.770K $21.33M
YoY Change -99.96%
Total Short-Term Liabilities $2.835M $23.92M $635.5K $1.433M
YoY Change -88.15% 3664.33% -55.67%
Long-Term Debt $150.3K $1.270M $18.74M $19.14M
YoY Change -88.17% -93.22% -2.07%
Other Long-Term Liabilities $0.00 $255.0K $167.7K $103.0K
YoY Change -100.0% 52.02% 62.84%
Total Long-Term Liabilities $150.3K $1.525M $18.91M $19.24M
YoY Change -90.15% -91.94% -1.72%
Total Liabilities $2.914M $24.87M $18.97M $20.11M
YoY Change -88.29% 31.11% -5.65%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020
Basic Shares Outstanding 3.960M shares 2.368M shares
Diluted Shares Outstanding 3.960M shares 2.368M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $2.3204 Million

About 60 DEGREES PHARMACEUTICALS, INC.

60 Degrees Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Industry: Pharmaceutical Preparations Peers: DMK PHARMACEUTICALS Corp AVENUE THERAPEUTICS, INC. CNS Pharmaceuticals, Inc. ELI LILLY & Co Eloxx Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. Hoth Therapeutics, Inc. PaxMedica, Inc. Pulmatrix, Inc. Virpax Pharmaceuticals, Inc.